Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

01 Apr 2011
Annual Information Update

April 1, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2010 and March 31, 2011.

The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date.  The information appears by way of record and the Company is under no obligation to update it.

1. Announcements made via a RIS

The documents listed below were published via a Regulatory Information Service on or around the dates indicated.

29-Mar-11 Holding(s) in Company
24-Mar-11 2010 Annual Report - DTR 6.3.5 Disclosure
21-Mar-11 FDA Assigns PDUFA Date for Shire's FIRAZYR®
03-Mar-11 EC Approves Self-Administration Label for FIRAZYR®
02-Mar-11 Correction : Director/PDMR Shareholding
01-Mar-11 Director/PDMR Shareholding
01-Mar-11 Total Voting Rights
01-Mar-11 Elections for Second Interim Dividend
28-Feb-11 Shire Files Complete Response to FDA
24-Feb-11 Shire Receives new Paragraph IV Notice Letter
10-Feb-11 Outstanding 2010 results: Non GAAP EPS up 21% to $4.23. Good earnings growth expected in 2011.
01-Feb-11 Total Voting Rights
31-Jan-11 Full Year 2010 results date notification
10-Jan-11 Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model
04-Jan-11 Total voting rights
03-Dec-10 INTUNIV - Shire Files Suit against Impax and Watson
01-Dec-10 Total Voting Rights
01-Dec-10 Positive Results From FAST-3 Study of FIRAZYR(R)
23-Nov-10 Blocklisting - Interim Review
10-Nov-10 Five-Year Market Exclusivity for VYVANSE® Upheld
09-Nov-10 Shire finalises its acquisition of Movetis NV
02-Nov-10 Director/PDMR Shareholding
01-Nov-10 Total Voting Rights
01-Nov-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter
29-Oct-10 Continued excellent performance in Q3
29-Oct-10 VYVANSE(R) - Shire Reports Positive Signal Finding Study
26-Oct-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter
18-Oct-10 Third quarter 2010 results date notification
13-Oct-10 Shire Acquires 99.21% of the shares of Movetis N.V.
01-Oct-10 Total Voting Rights
30-Sep-10 Results of the Tender Offer for Movetis NV
09-Sep-10 Shire Expands Pipeline to Treat Orphan Muscle Diseases
06-Sep-10 Re Acquisition
01-Sep-10 Total Voting Rights
01-Sep-10 Elections for Interim Dividend
26-Aug-10 Shire Announces European Approval of VPRIV#
26-Aug-10 Notification of major interests in shares
24-Aug-10 Pentasa - Shire Receives Ruling From FDA
20-Aug-10 Correction - Director/PDMR Shareholding
20-Aug-10 Director/PDMR Shareholding
17-Aug-10 Director/PDMR Shareholding
11-Aug-10 Half Yearly Report - Part 1
11-Aug-10 Half Yearly Report - Part 3
11-Aug-10 Half Yearly Report - Part 2
11-Aug-10 Half Yearly Report - Part 4
11-Aug-10 Shire agrees to divest Daytrana(R) to Noven
05-Aug-10 Director/PDMR Shareholding
04-Aug-10 Shire delivers excellent Q2 performance - Part 3
04-Aug-10 Shire delivers excellent Q2 performance - Part 2
04-Aug-10 Shire delivers excellent Q2 performance - Part 1
03-Aug-10 Shire Proposes to Expand Specialist GI Portfolio
02-Aug-10 Total Voting Rights
15-Jul-10 Second quarter 2010 results date notification
08-Jul-10 Lialda - Shire Files Suit against Zydus
01-Jul-10 Total Voting Rights
30-Jun-10 Shire Purchases Strategic Site in Massachusetts
25-Jun-10 Shire Receives CHMP Positive Opinion for VPRIV
21-Jun-10 Director/PDMR Shareholding
17-Jun-10 Directorate Change
03-Jun-10 Shire Files Suit against Anchen
01-Jun-10 Total Voting Rights
01-Jun-10 Shire Receives Paragraph IV Notice Letter
24-May-10 Blocklisting - Interim Review
13-May-10 INTUNIV[TM] - Shire Files Suit against Actavis
04-May-10 Total Voting Rights
29-Apr-10 1st Quarter Results
27-Apr-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter
27-Apr-10 Result of AGM
23-Apr-10 INTUNIV - Shire Files Suit against Teva
20-Apr-10 1st qtr. 2010 results date notification - April 29, 2010
06-Apr-10 Shire Receives 2nd INTUNIV Paragraph IV Notice Letter
01-Apr-10 Total Voting Rights
01-Apr-10 Annual Information Update
01-Apr-10 Director/PDMR Shareholding

2. Documents filed with the Securities and Exchange Commission (“SEC”)

The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ.  Full details of these filings can be found on the SEC’s website at www.sec.gov.

3. Documents filed with Companies Registry, Jersey

Date of DeliveryDocument
21-Feb-11Annual Return
06-May-10Special Resolution passed on April 27, 2010
26-Apr-10Annual Report and Accounts for the year ended December 31, 2009

4. Documents sent to Shareholders

The following documents were published and sent to shareholders, and are available on the Company’s website.

Date of DeliveryDocument
24-Mar-11Annual Report and Accounts for the year ended December 31, 2010
24-Mar-11Notice of 2011 Annual General Meeting

A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.

Tony Guthrie
Deputy Company Secretary

 

For further information please contact:

Investor RelationsEric Rojas erojas@shire.com+1 781 482 0999

 

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

01 Apr 2011 Annual Information Update (42KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?